Abcellera Biologics Inc Asset Resilience Ratio
Abcellera Biologics Inc asset resilience ratio. Abcellera Biologics Inc (ABCL) has an Asset Resilience Ratio of 32.12% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ABCL days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Abcellera Biologics Inc (2020–2025)
Asset resilience ratio of Abcellera Biologics Inc from 2020 to 2025. This chart shows how Abcellera Biologics Inc's Asset Resilience Ratio has changed over time. Read ABCL current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Abcellera Biologics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ABCL total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $420.04 Million | 32.12% |
| Total Liquid Assets | $420.04 Million | 32.12% |
Asset Resilience Insights
- Very High Liquidity: Abcellera Biologics Inc maintains exceptional liquid asset reserves at 32.12% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Abcellera Biologics Inc Industry Peers by Asset Resilience Ratio
Compare Abcellera Biologics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Abcellera Biologics Inc Asset Resilience Ratio by Year (2020–2025)
Abcellera Biologics Inc asset resilience ratio by year from 2020 to 2025. The table below shows the annual Asset Resilience Ratio data for Abcellera Biologics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 29.87% | $405.31 Million | $1.36 Billion | -4.62pp |
| 2024-12-31 | 34.49% | $469.29 Million | $1.36 Billion | -7.66pp |
| 2023-12-31 | 42.15% | $627.26 Million | $1.49 Billion | +9.71pp |
| 2022-12-31 | 32.45% | $499.95 Million | $1.54 Billion | +13.73pp |
| 2021-12-31 | 18.72% | $246.84 Million | $1.32 Billion | -40.36pp |
| 2020-12-31 | 59.08% | $594.12 Million | $1.01 Billion | -- |
About Abcellera Biologics Inc
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for… Read more